Consensus estimates for Q2 2026 project revenue at $15.45 billion and earnings at $2.50 per share, as the current stock price of $169.26 trades significantly below the average analyst target of $211.00.
Investors are primarily focused on management's response to the recent Phase III trial failure of the heart disease drug Wainua, which has raised concerns about the company's long-term research engine.
The performance of the Oncology franchise remains the critical growth engine, with analysts seeking confirmation that blockbusters like Tagrisso and Enhertu can maintain double-digit momentum.
Sustained strength in these core cancer therapies is vital to offsetting recent pipeline setbacks and supporting the company’s ambitious goal of reaching $80 billion in annual revenue by 2030.